Revlimid ranked as the second best-selling drug in the world last year, with sales of nearly $8.2 billion. Market research company EvaluatePharma predicts that the drug will slip one spot by 2024 but will rake in around $11.9 billion. Revlimid contributes 64% of total revenue for Celgene(NASDAQ:CELG). And yet the big biotech's CEO just said that he "wants to make Revlimid obsolete." Say what?